Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26978594 | 1.00 | CDK1 (0.47) | CDK1FAAHPPARGPPARAS1PR2 | |
| SCHEMBL26110029 | 0.89 | CHRM2 (0.37) | CDK1 | |
| SCHEMBL30975320 | 0.83 | CDK1 (0.47) | CDK1FAAHPPARGPPARA | |
| SCHEMBL31490070 | 0.83 | CDK1 (0.44) | CDK1FAAHPPARGPPARA | |
| SCHEMBL29374627 | 0.82 | CYP19A1 (0.43) | — | |
| SCHEMBL26980591 | 0.82 | CYP19A1 (0.43) | — | |
| SCHEMBL28526539 | 0.82 | CDK1 (0.54) | CDK1PPARGPPARA | |
| SCHEMBL7062043 | 0.82 | CDK1 (0.41) | CDK1FAAHPPARGPPARAS1PR2 | |
| SCHEMBL2541124 | 0.81 | HTT (0.49) | CDK1PPARGPPARA | |
| SCHEMBL29377070 | 0.81 | CYP19A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116472273-A | Antidiabetic compounds and compositions | 宁康瑞珠生物制药(珠海)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2022028317-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2022-02-10 | — | — | WO | disclosed |